A consortium of leading global investors including Temasek and Sequoia Capital China has joined the $90-million Series A financing round of Shanghai-based biotech startup JW Therapeutics, according to an official announcement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
